Circular Dichroism
Talk to Our Scientists
"*" indicates required fields
Circular Dichroism (CD)
Most structural failures in biotherapeutic development are caught late. CD moves that detection earlier: it provides direct spectroscopic evidence of folding state and conformational response to buffer, pH, and excipient conditions, without labelling or modifying the sample. The data is relevant from candidate selection through comparability assessment.
How CD Works
Circular dichroism quantifies how a chiral sample absorbs left- and right-handed circularly polarized light differently. In proteins, this asymmetry arises from the folded structure itself: peptide bonds, aromatic residues, and disulfide bridges each sit in a unique stereochemical environment, producing a signal characteristic of the overall conformation.
The resulting CD spectrum is a direct readout of secondary structure content. Alpha-helices, beta-sheets, random coils, and turns each produce characteristic spectral signatures in the far-UV region (190–250 nm). Near-UV CD (250–350 nm) reports on the tertiary environment of aromatic residues and disulfides, providing a fingerprint of the folded three-dimensional structure.
CovalX instrument specifications:
- Wavelength range: 163 – 900 nm
- Peltier temperature control: 4°C – 95°C
- Variable temperature and variable wavelength acquisition modes
- Non-destructive, label-free measurement
Applications
Secondary structure determination
Quantify alpha-helix, beta-sheet, and random coil content directly from far-UV CD spectra. Deconvolution algorithms provide percentage estimates comparable across conditions and constructs. This is particularly relevant for confirming that a recombinant protein or biotherapeutic has adopted the expected fold after expression and purification.
Antibody and mAb characterization
CD is routinely applied to monoclonal antibodies and antibody-drug conjugates to confirm correct folding, compare structural integrity across production runs or expression systems, and detect conformational changes induced by mutation, conjugation, or antigen binding. Under stress conditions, it provides a direct readout of aggregation-driven structural loss.
Formulation and buffer screening
Systematic CD measurements across pH, ionic strength, and excipient conditions identify the formulation space that preserves native conformation.
Biosimilar comparability
CD thermograms and spectra are accepted as supporting structural data in biosimilar comparability packages submitted to FDA and EMA. They provide orthogonal evidence of structural equivalence alongside MS-based methods.
Technical Notes
CD measurements at CovalX are performed on a spectropolarimeter with Peltier temperature control. Sample requirements and buffer compatibility are discussed at project setup.
-
Buffer absorbance in the far-UV range is the primary constraint. High chloride concentrations (>50 mM NaCl), glycerol, and many detergents absorb strongly below 210 nm and limit usable spectral range.
- Protein concentration typically in the 0.1–0.5 mg/mL range for far-UV; higher for near-UV.
- Path length is adjusted (1 mm cells for far-UV, 10 mm for near-UV) to keep absorbance within acceptable limits.
- High-tension voltage across the spectrum is reported to flag data quality in low-transmission regions.
Regulatory Context
CD is recognized under ICH Q6B as a method for physicochemical characterization of biotherapeutics, covering secondary structure and conformational integrity. CD data is routinely included in IND and BLA submissions as part of the structural characterization package and is expected in biosimilar dossiers by both FDA and EMA, alongside other orthogonal methods, such as DSC.
One CRO, coordinated data
DSC is part of CovalX’s biophysical characterization offering. It complements the MS-based services available in-house across the same molecule and the same sample.
Running biophysical and structural analyses through a single CRO reduces sample quantity requirement, allows coordinated experimental design, consistent sample handling, and consolidated reporting. For regulatory packages requiring orthogonal characterization data from multiple methods, that continuity matters.